Treatment
PCSK9 inhibitor clinical trials
We’re tracking 19 recruiting studies that include PCSK9 inhibitor, each written for real people, not researchers, below.
Recruiting studies
- NCT04731155RecruitingPhase 4
Test early PCSK9 medicine to prevent heart problems after a heart attack
This trial studies whether starting a cholesterol-lowering medicine called a PCSK9 inhibitor early after a heart attack can improve heart health and outcomes. It focuses on people who had a recent heart-artery procedure to fix the blockage in the left anterior descending (LAD) artery.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06863545Recruiting
PCSK9 Inhibitors for High-Risk Coronary Plaques on CT
This study tests whether adding a PCSK9 inhibitor (a newer cholesterol-lowering shot) to standard treatment can reduce heart risks in people who have certain high-risk plaque features seen on a CT scan of their heart arteries.
Hangzhou, ZhejiangAges 18 years+ - NCT04968509RecruitingPhase 3
PCSK9 shots for calcified aortic valve narrowing
This study tests whether adding PCSK9 inhibitor injections (to statin treatment) can slow or improve calcific aortic valve stenosis, a condition where the heart’s aortic valve becomes stiff and narrowed. It’s aimed at adults with mild-to-moderate disease or certain people with severe disease but no symptoms.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07036991Recruiting
Comparing two treatments for narrowed neck arteries
This trial tests whether adding a PCSK9 inhibitor to a statin is better than a statin alone for people with mild-to-moderate narrowing of the carotid artery (the main artery in the neck). It looks at how well these treatments slow plaque buildup and prevent strokes.
ShanghaiAges 18 years+ - NCT06520904RecruitingPhase 4
PCSK9 inhibitor for coronary plaque in heart disease
This study tests whether a medication called a PCSK9 inhibitor (a type of drug that lowers bad cholesterol) can improve the buildup of plaque in heart arteries. It may be an option for people with coronary artery disease who have not been helped enough by statins alone.
Ürümqi, XinjiangAges 18–65 - NCT07208006Recruiting
Early cholesterol-lowering drug after heart attack
This trial tests whether giving a powerful cholesterol-lowering drug (PCSK9 inhibitor) very early after a heart attack can help prevent further heart problems. It is for people who have had a recent heart attack and have blockages in more than one heart artery.
Shanghai, Shanghai MunicipalityAges 18–100 - NCT07058077RecruitingPhase 2/Phase 3
Study of oral cholesterol-lowering pill in children with HeFH
This study tests an experimental daily pill (enlicitide decanoate) that lowers LDL ('bad') cholesterol in children and teens with a genetic condition called heterozygous familial hypercholesterolemia (HeFH). It aims to see if this medicine can safely help reduce their high cholesterol levels.
Wilmington, DelawareAges 6–17 - NCT07704918Recruiting
Study: Lowering cholesterol during melanoma immunotherapy
This study tests whether giving aggressive cholesterol-lowering medication to people starting immunotherapy for melanoma can improve heart health. It may help reduce the risk of heart problems during cancer treatment.
Aurora, ColoradoAges 55 years+ - NCT05292404RecruitingPhase 4
PCSK9 medicine soon after heart attack to protect the heart
This trial studies whether starting a PCSK9-blocking medicine early after a specific type of heart attack can improve heart outcomes. You may be eligible if you have a STEMI heart attack soon, are planning a procedure to open the blocked artery, and meet safety and pregnancy criteria.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT03753555RecruitingPhase 4
High-intensity statin treatment for certain stroke artery plaque cases
This trial tests whether a higher-dose statin can help after an ischemic stroke in people who have specific plaque patterns in brain blood vessels. It may help lower the risk of another stroke by targeting the artery plaque process.
ShenyangAges 18–80 - NCT04847752Recruiting
Predicting outcomes after stroke from artery plaque
This study looks at factors that can help predict recovery and risk after an ischemic stroke caused by plaque buildup in a major artery. It may help doctors better forecast prognosis and tailor follow-up care for people like you.
WuhanAges Up to 80 years - NCT05397405Recruiting
Improving cholesterol control after narrowing in brain arteries
This study looks at strategies to improve cholesterol treatment in adults whose brain arteries are narrowed and who have had symptoms. Better cholesterol management may help reduce future problems related to this condition.
Nanjing, JiangsuAges 18–85 - NCT05430828Recruiting
Study of staying on PCSK9 injections and health outcomes
This study follows people who are already taking PCSK9 inhibitor shots to see how well patients stay on treatment and how effective it is. Your participation would mainly be about consenting to provide basic information and possibly follow-up details.
ArzignanoAges 18–80 - NCT06649240Recruiting
Best LDL cholesterol goal after small vessel stroke
This trial is testing the best target for 'bad' cholesterol (LDL) after a type of stroke caused by a small blocked vessel. You would be in one of two groups to see which LDL level helps prevent another stroke the most.
AnsanAges 19 years+ - NCT06738758Recruiting
Early intensive cholesterol-lowering study for acute coronary syndrome
This study tests whether starting strong cholesterol-lowering treatment early in the hospital can improve outcomes for people with acute coronary syndrome (a serious heart condition like a heart attack or unstable angina). It may help if you have high LDL cholesterol.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06902740RecruitingPhase 4
PCSK9 inhibitor with statin for asymptomatic brain artery narrowing
This trial tests whether adding a PCSK9 inhibitor to standard statin therapy can help people with narrowing in brain arteries that hasn't caused symptoms yet. The goal is to see if this combination lowers plaque and prevents future strokes.
Beijing, Beijing MunicipalityAges 18–80 - NCT07404553RecruitingPhase 2/Phase 3
Study of SHR-1918 for high cholesterol not controlled by statins and PCSK9 inhibitors
This trial tests a new medicine, SHR-1918, for people whose bad cholesterol (LDL-C) stays high even when they take statins and another type of cholesterol-lowering drug called a PCSK9 inhibitor. It aims to see if this additional treatment can lower their cholesterol more effectively.
Nanjing, JiangsuAges 18–85 - NCT07468630RecruitingPhase 2
Tocilizumab plus chemoimmunotherapy for advanced colon cancer
This study tests a new combination of medications for people with locally advanced colon cancer. It aims to see if adding tocilizumab to standard chemo-immunotherapy can help shrink or control the tumor.
Chongqing, Chongqing MunicipalityAges 18–80 - NCT07540741Recruiting
PCSK9 Inhibitors for Large-Artery Stroke Recovery
This trial tests whether a cholesterol-lowering medication called evolocumab (a PCSK9 inhibitor) can help people recover better after a specific type of stroke caused by clogged arteries. The study checks if lowering cholesterol further than usual statins do improves stroke outcomes and is safe.
HeilongjiangAges 18–80
What PCSK9 inhibitor is being studied for
Conditions with recruiting PCSK9 inhibitor studies.
Common questions
- Are there clinical trials studying PCSK9 inhibitor?
- Yes. Clin2 currently lists 19 recruiting studies that include PCSK9 inhibitor, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a PCSK9 inhibitor trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is PCSK9 inhibitor an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether PCSK9 inhibitor or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.